Among patients with relapsing-remitting multiple sclerosis , daclizumab HYP showed efficacy superior to that of interferon beta-1a with regard to the annualized relapse rate and lesions , as assessed by means of MRI , but was not associated with a significantly lower risk of disability progression confirmed at 12 weeks .